MaxCyte, Inc. announced on November 9, 2026, that it has entered into a definitive Securities Purchase Agreement to acquire Akron BioProducts LLC. The transaction, valued at $105 million in cash, is expected to close before the end of 2026.
Under the terms of the agreement, MaxCyte will pay $105 million in cash at closing, subject to customary adjustments. Additionally, the company will issue 20,639,733 shares of its common stock and provide $20 million in guaranteed, deferred cash payments. These deferred payments consist of $10 million due on the first business day of 2028 and $10 million due on the first business day of 2029.
The sellers of Akron Bio are Ohio TopCo LP and Arcline Capital Partners A LP, affiliates of Arcline Investment Management. The acquisition is not contingent on securing new financing or stockholder approval. However, the closing is subject to standard conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period and approval of the stock consideration for listing on Nasdaq.
Following the acquisition, the sellers will be subject to a six-month lock-up period on the shares they receive. Concurrently, the parties will enter into a registration rights agreement to facilitate the resale of the shares.
In related financial news, MaxCyte reported total revenue of $10.2 million for the third quarter of 2026, a 49% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance to at least $34.5 million, excluding the impact of the Akron acquisition. As of September 30, 2026, the company held $132.7 million in cash, cash equivalents, and investments.
